MedTrace Logo

Biomarkers in Parkinsonian Syndromes

NCT02114242 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-03-31

No results posted yet for this study

Summary

Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein, while tau protein accumulates in PSP. The development of biological markers for the diagnosis and prognosis in PD, MSA and PSP remains an unmet need. Such biological markers are crucial for future disease-modification and neuroprotection trials. Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature in PD and MSA. The oligomeric alpha-synuclein seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies.

The main objective is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and PSP patients. PD and MSA patients will receive Cerebrospinal Fluid (CSF) and blood sampling at two study visits (baseline and after 12 months). Major secondary objectives are (i) to assess potential associations between the biomarker and clinical measures of disease severity and progression in MSA and PSP, and (ii) to assess the variation of the biomarker and its correlation to disease severity and progression in PD, MSA and PSP.

Conditions

Interventions

OTHER

CSF, blood and urine sampling

PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).

OTHER

clinical measures of disease severity and progression

Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Wassilios MEISSNER, Pr · University Hospital, Bordeaux

  • Rodolphe THIEBAUT, MD · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-16
Primary Completion
2023-12-16
Completion
2025-12-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02114242 on ClinicalTrials.gov